SAVE-Care (Sodium Glucose Cotransporter-2 Inhibitors [SGLT2i] As Novel Gout Care) Trial
A legfontosabb adatok
- Hol
- Boston (Egyesült Államok)A helyszín megnézése
- Fázis
- 4. fázis
Neked szólhat?
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 80 év között vagy?
Forrás: NCT06674109: ki vehet részt
Helyszínek itt: Egyesült Államok
- Massachusetts General HospitalBoston, Egyesült ÁllamokContact: Hyon K Choi, MDRésztvevőt keres
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakA vizsgálat adatai
- Ki végzi
- Massachusetts General Hospital
- Azonosító
- NCT06674109
- A regiszteradat frissítve
- 2026. augusztus 5.
- Eredeti leírás
SAVE-Care (Sodium Glucose Cotransporter-2 inhibitors [SGLT2i] As Novel Gout Care) Trial is a double-blind randomized placebo-controlled trial (RCT) designed to assess the effect of empagliflozin on serum urate [SU] levels of gout patients, as well as levels of highly-sensitivity C-reactive protein [hsCRP] and interleukin 6 [IL-6], and estimate gout flares over 3 months, in order to develop a full-scale RCT of clinical endpoints to directly inform gout care guidelines.A teljes eredeti leírásKevesebb
SAVE-Care (SGLT2i As Novel Gout Care) Trial
SAVE-Care (Sodium Glucose Cotransporter-2 inhibitors [SGLT2i] As Novel Gout Care) Trial is a double-blind randomized placebo-controlled trial (RCT) designed to assess the effect of empagliflozin on serum urate [SU] levels of gout patients, as well as levels of highly-sensitivity C-reactive protein [hsCRP] and interleukin 6 [IL-6], and estimate gout flares over 3 months, in order to develop a full-scale RCT of clinical endpoints to directly inform gout care guidelines.
Bevonási feltételek: In order to be eligible to participate in this study, an individual must meet all of the following criteria:; Provision of signed and dated informed consent form; Fulfilling American College of Rheumatology [ACR]/European Alliance of Associations for Rheumatology [EULAR] gout criteria; 1+ gout flares in last 12 months; Serum urate level ≥ 6mg/dl; Males and females; Age 18-80; Willingness to adhere to the study intervention procedures.
Kizáró feltételek: Colchicine or nonsteroidal anti-inflammatory drug [NSAID] prophylaxis; Use of anti-obesity drugs; active cardiovascular disease [CVD], type-1 diabetes; Presence of a condition(s) or diagnosis, either physical or psychological, or physical exam finding that precludes participation. [History of ketoacidosis, end-stage or decompensated liver disease, active cancer]; Estimated Glomerular Filtration Rate [eGFR] <20ml/min; An individual who meets any of the following criteria will be excluded from participation in this study:; pregnant and lactating women; Basal-bolus or multiple daily injection insulin regimens, or loop diuretics.